WebDoctor Encyclopedia

Head & neck

Hyalinising clear cell carcinoma of the salivary gland

Hyalinising clear cell carcinoma is a rare, usually low-grade salivary gland cancer that most often appears in the palate or tongue base. An EWSR1 gene test confirms the diagnosis. Surgery with clear margins usually controls it well.

Medically reviewed Last reviewed October 20, 2026

What is hyalinising clear cell carcinoma of the salivary gland?

Hyalinising clear cell carcinoma (HCCC) is a rare, usually low-grade cancer of the salivary glands. It most often grows in the minor salivary glands, the hundreds of tiny glands scattered through the lining of the mouth and throat. Common sites include the palate, the base of the tongue and the nasopharynx, the space behind the nose.

The name describes the tumour’s appearance under the microscope. Many of its cells have clear cytoplasm, and they grow in cords and nests within dense, glassy, scar-like tissue called hyalinised stroma. In the most recent World Health Organization (WHO) classification, the tumour is called simply clear cell carcinoma of the salivary gland.

For many years, HCCC was a diagnosis of exclusion, made only after ruling out other tumours with clear cells. In 2011, researchers discovered that most cases carry a specific gene fusion, EWSR1::ATF1 (Antonescu et al., 2011). This test now allows pathologists to identify the tumour with confidence (Weinreb, 2013).

HCCC usually appears as a slow-growing, painless lump in the mouth. The main treatment is surgery with clear margins. Radiotherapy is added for higher-risk tumours. The outlook is usually good, although some tumours return locally and a minority spread to lymph nodes or further.

1. Key facts at a glance

Feature Details
Type of cancer Salivary gland carcinoma (WHO name: clear cell carcinoma)
Usual site Minor salivary glands, especially palate and base of tongue
Typical age Usually middle-aged and older adults
Genetic hallmark EWSR1::ATF1 fusion in most cases
Main symptom A painless lump or swelling in the mouth
Grade Mostly low grade; a high-grade form exists
Main treatment Surgery with clear margins; radiotherapy for higher-risk tumours
Outlook Generally good; 10-year disease-specific survival about 80% in one large series

2. Types

Low-grade and high-grade HCCC

A study of 87 tumours from seven centres proposed a two-tier grading system (Xu et al., 2025).

Grade Definition Behaviour
Low grade Few dividing cells and no tumour necrosis Usually slow-growing
High grade Five or more mitoses per 2 mm2 and/or tumour necrosis Higher risk of nodal spread and shorter survival

Tumours that look similar

Tumour How it differs
Mucoepidermoid carcinoma Has MAML2 gene fusions; may be wrongly graded higher than HCCC
Epithelial-myoepithelial carcinoma Has two layers of cells; no EWSR1::ATF1 fusion
Myoepithelial carcinoma Myoepithelial markers positive
Clear cell odontogenic carcinoma Arises in the jaw bone; shares EWSR1 rearrangement and is closely related
Metastatic clear cell renal carcinoma Spread from the kidney; must be excluded

Distinguishing HCCC from mucoepidermoid carcinoma is particularly important, because grading systems for the latter can make HCCC look more aggressive than it is, which may lead to overtreatment (Antonescu et al., 2011).

The salivary glands

Gland type Location Share of salivary tumours that are cancer
Parotid glands In front of the ears Lower
Submandibular glands Under the jaw Intermediate
Sublingual glands Under the tongue Higher
Minor salivary glands Throughout the lining of the mouth, throat and nose Higher

Tumours of the minor salivary glands are more likely to be cancerous than those of the large parotid glands. HCCC is one of the cancers that shows a strong preference for these small glands: in the Xu series, about nine in ten tumours arose in minor glands.

How molecular testing changed the picture

Before the gene fusion was discovered, pathologists could only diagnose HCCC by excluding other clear cell tumours. This was difficult, and some tumours were labelled as more aggressive types. The finding of the EWSR1::ATF1 fusion changed this. It is present in the great majority of cases and absent from most tumours that look similar under the microscope (Antonescu et al., 2011).

Molecular testing also revealed that HCCC can show a wider range of appearances than first thought. Tumours with recurrence, spread or high-grade features have been confirmed as HCCC by this test (Weinreb, 2013). Today, the test is a routine part of diagnosis in specialist centres.

3. Causes and risk factors

The cause of HCCC is not known.

Factor Notes
EWSR1::ATF1 fusion Present in the tumour cells only; not inherited
Age Mainly adults
Sex Reported somewhat more often in women
Smoking, alcohol, HPV No established link
Previous radiotherapy Not established as a risk factor

4. How does it look

In the mouth

Feature Description
Appearance A smooth swelling or lump beneath normal-looking lining
Feel Firm
Surface Usually intact; occasional ulceration
Growth Slow, sometimes over years

In a review of 254 cases, the most common presentation was a painless mass on the palate. Symptoms had been present for anything from one week to six years (Desai et al., 2022).

On scans

Test Purpose
MRI Shows the extent of the tumour in soft tissue
CT Shows bone involvement, for example of the palate or maxilla
Neck ultrasound Checks lymph nodes
PET-CT Considered for high-grade or advanced tumours

Under the microscope

Feature Description
Cells Clear cells and pink (eosinophilic) cells; pink cells are often more numerous
Patterns Nests, cords, trabeculae and sheets
Stroma Dense hyalinised bands
Stains Cytokeratins and p63 positive; S-100 and smooth muscle markers negative
Molecular test EWSR1 rearrangement by FISH, or EWSR1::ATF1 by RNA sequencing

In the Xu study, 97% of tumours tested had an EWSR1 rearrangement, and nearly half showed perineural invasion, meaning growth along nerves.

5. Symptoms

Common symptoms

  • A painless lump in the roof of the mouth or another part of the mouth
  • Swelling at the base of the tongue
  • A feeling of something in the throat

Less common symptoms

Symptom Possible cause
Nasal blockage or bleeding Tumour in the nasopharynx or nasal cavity
Difficulty swallowing Tumour at the base of the tongue
Change in voice Tumour in the throat
Numbness or pain Growth along nerves
Loose teeth or ill-fitting denture Involvement of the upper jaw
Lump in the neck Lymph node spread

When to seek medical advice

See your doctor or dentist about any lump in the mouth or throat lasting more than three weeks, especially if it is growing.

6. Diagnosis

Test Purpose
Examination of the mouth and throat Assesses the lump
Nasendoscopy Views the nose and throat with a thin camera
Biopsy Confirms the diagnosis
Immunostains Separate HCCC from similar tumours
EWSR1 FISH or RNA sequencing Confirms the genetic hallmark
MRI and CT Show the tumour’s extent
Neck imaging Looks for lymph node spread

Staging follows the TNM system for the site where the tumour started, such as the oral cavity or pharynx.

7. Treatment

Surgery

Aspect Details
Aim Remove the tumour with a margin of healthy tissue
Palate tumours May require removal of part of the hard palate, replaced by a prosthesis or reconstruction
Base of tongue tumours Transoral or open approaches
Neck dissection If neck nodes are involved; sometimes for high-grade tumours

Radiotherapy

Situation Role
Close or positive margins Reduces the risk of local recurrence
Perineural invasion Often considered
High-grade tumours Often recommended
Lymph node spread Treats the neck
Tumours that cannot be removed Main treatment

Chemotherapy and targeted therapy

Situation Notes
Early-stage HCCC Not used
Widespread disease No standard drug; treatment decided case by case or in clinical trials

Treatment by situation

Situation Typical approach
Small low-grade tumour, clear margins Surgery alone, then follow-up
Close margins or nerve involvement Surgery and radiotherapy
High-grade tumour Surgery, neck treatment and radiotherapy
Recurrence Further surgery and/or radiotherapy

Recovery after surgery

Period What to expect
First days Soft or liquid diet; pain relief; mouth rinses
1-2 weeks Healing of the surgical site; temporary prosthesis if part of the palate was removed
2-6 weeks Gradual return to a normal diet; speech improves
2-3 months A definitive prosthesis may be fitted once healing is complete
After radiotherapy Mouth soreness settles over several weeks; dry mouth may persist

Eating and speaking after palate surgery

When part of the palate is removed, there can be an opening between the mouth and the nose. This can make speech sound nasal and allow food or liquid into the nose. A dental specialist called a prosthodontist can make a plate, called an obturator, that closes the gap.

Many people find that their speech and eating return close to normal with a well-fitting obturator. Alternatively, surgeons may close the defect with tissue from elsewhere in the body.

Side effects

Treatment Possible side effects
Palate surgery Speech and swallowing changes until a prosthesis or reconstruction is fitted
Base of tongue surgery Swallowing difficulty, change in taste
Neck dissection Shoulder stiffness, numbness
Radiotherapy Sore mouth, dry mouth, taste loss, tooth decay, jaw stiffness

8. Outlook (prognosis)

Measure Result
10-year disease-specific survival About 80%
10-year disease-free survival About 51%
10-year distant metastasis-free survival About 87%
Local recurrence in pooled reports About 19%
Any spread in pooled reports About 14%

The survival figures come from Xu et al. (2025), and the recurrence and spread figures from Desai et al. (2022).

Factors affecting the outlook

Factor Effect
High mitotic rate Independent predictor of recurrence
Tumour necrosis Poorer survival
Lymphovascular invasion Higher risk of nodal spread and recurrence
Nuclear pleomorphism and atypical mitoses Poorer survival
Nodal spread Higher risk of distant spread

The relatively low disease-free survival shows that recurrence is not rare, even though most patients survive their disease. Long-term follow-up is therefore important.

9. Follow-up

Time Typical checks
Years 1-2 Examination every 2-3 months; imaging as needed
Years 3-5 Every 4-6 months
After 5 years Yearly, as recurrence can be late
After radiotherapy Dental reviews and thyroid tests if the neck was treated

10. Living with hyalinising clear cell carcinoma

  • Visit your dentist before and regularly after radiotherapy
  • Use fluoride products and saliva substitutes if your mouth is dry
  • Work with speech and swallowing therapists after surgery
  • Wear and care for your palatal prosthesis as advised
  • Stop smoking and limit alcohol to support healing
  • Report new lumps, pain or numbness promptly
  • Seek support from head and neck cancer charities

11. Frequently asked questions

Question Answer
Is it a serious cancer? Most are low grade with a good outlook, but follow-up is needed
Why was the name changed? The WHO now calls it clear cell carcinoma; HCCC remains widely used
What is the EWSR1::ATF1 test? A genetic test on the tumour that confirms the diagnosis
Will I need radiotherapy? Only for certain risk features, such as close margins or high grade
Can it come back? Yes, in some patients, sometimes years later
Is it caused by smoking? No link has been established
Is it inherited? No
Will I be able to eat normally? Most people return to a normal or near-normal diet after recovery
Do I need chemotherapy? Not usually; it is reserved for widespread disease

12. Questions to ask your care team

  • Has the diagnosis been confirmed by EWSR1 testing?
  • Is my tumour low grade or high grade?
  • Were the margins clear?
  • Do I need radiotherapy or neck treatment?
  • How will treatment affect my speech, swallowing and teeth?
  • How often will I be checked, and for how long?
  • Will I need a prosthesis or reconstruction, and who will provide it?
  • Should I see a dentist before treatment starts?
  • Is there a speech and language therapist or dietitian on the team?
  • Who should I call if I notice a new lump or ulcer between appointments?
  • Can my case be reviewed at a specialist head and neck centre?

Resources

  1. Antonescu, C.R. et al. (2011) ‘EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland’, Genes, Chromosomes and Cancer, 50(7), pp. 559-570.
  2. Desai, A. et al. (2022) ‘Clear cell carcinoma: a comprehensive literature review of 254 cases’, International Journal of Oral and Maxillofacial Surgery, 51(6), pp. 705-712.
  3. Weinreb, I. (2013) ‘Hyalinizing clear cell carcinoma of salivary gland: a review and update’, Head and Neck Pathology, 7(Suppl 1), pp. S20-S29.
  4. Xu, B. et al. (2025) ‘Hyalinizing clear cell carcinoma of the head and neck: a multicenter retrospective study of 87 cases focusing on prognostic pathologic features and grading scheme’, Modern Pathology, 38(11), 100834.
  5. National Cancer Institute (2026) Salivary Gland Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/head-and-neck/hp/adult/salivary-gland-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.